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Cumulative Mutagenesis of the Basic Residues in the
201–218 Region of Insulin-Like Growth Factor (IGF)-
Binding Protein-5 Results in Progressive Loss of Both
IGF-I Binding and Inhibition of IGF-I Biological Action
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Kirsten Phillips, Roger A. Clegg, Iain F. Gow, James Beattie, and David J. Flint
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Kingdom; and Institute of Biomedical and Life Sciences, University of Glasgow (S.M.K.), Glasgow G12 8QQ, Scotland,
United Kingdom
We have reported previously that mutation of two conserved
nonbasic amino acids (G203 andQ209) within the highly basic
201–218 region in the C-terminal domain of IGF-binding pro-
tein-5 (IGFBP-5) decreases binding to IGFs. This study reveals
that cumulative mutagenesis of the 10 basic residues in this
region, to create the C-Term series of mutants, ultimately re-
sults in a 15-fold decrease in the affinity for IGF-I and amajor
loss in heparin binding.We examined the ability ofmutants to
inhibit IGF-mediated survival of MCF-7 cells andwere able to
demonstrate that this depended not only upon the affinity for
IGF-I, but also the kinetics of this interaction, because
IGFBP-5 mutants with similar affinity constants (KD) values,
but with different association (Ka) and dissociation (Kd) rate
values, had markedly different inhibitory properties. In con-
trast, the affinity for IGF-I provided no predictive value in
terms of the ability of these mutants to enhance IGF action
when bound to the substratum. Instead, these C-Term mu-
tants appeared to enhance the actions of IGF-I by a combina-
tion of increased dissociation of IGF-IGFBP complexes from
the substratum, together with dissociation of IGF-I from IG-
FBP-5 bound to the substratum. These effects of the IGFBPs
were dependent upon binding to IGF-I, because a non-IGF
bindingmutant (N-Term)wasunable to inhibit or enhance the
actions of IGF-I. These results emphasize the importance of
the kinetics of association/dissociation in determining the en-
hancing or inhibiting effects of IGFBP-5 and demonstrate the
ability to generate an IGFBP-5 mutant with exclusively IGF-
enhancing activity. (Endocrinology 147: 338–349, 2006)
THE IGFs ARE important mediators of physiologicalgrowth, which exert their cellular actions by binding to
and activating the type 1 IGF receptors. In turn, IGF receptor
interactions are regulated by a family of six IGF-binding
proteins (IGFBPs) that form high affinity complexes with
both IGF-I and IGF-II (reviewed in Ref. 1). The IGFBP pro-
teins all share a common protein structure that can concep-
tually be divided up into three domains (1) (see Fig. 1). There
is a particularly high degree of conservation in the N- and
C-terminal domains, with all IGFBPs containing six cysteine
residues in the C-terminal domain of all species sequenced
to date, whereas IGFBP-1 to -5 have 12 and IGFBP-6 has 10
cysteines in the N-terminal domain. A nonconserved region
separating the N- and C-terminal domains contains most of
the sites for proteolysis and posttranslational modifications
of the proteins. IGFBP-5 is the most highly conserved of the
IGFBP proteins; 95% conserved between human and mouse
in the central domain and over 98% conserved in the N- and
C-terminal domains. Both the N- and C-terminal cysteine-
rich domains of IGFBPs have been demonstrated to contrib-
ute to the IGF-binding sites. This is supported by work in
which fragments from the N-terminal cysteine-rich domains
of IGFBP-1 (2), IGFBP-3 (3), IGFBP-4 (4), and IGFBP-5 (5, 6)
and C-terminal cysteine-rich domains of IGFBP-2 (7, 8) and
IGFBP-3 (3) were generated and shown to possess residual
IGF-binding activity. Other groups have reported biosensor
analysis of N- and C-terminal fragments of bovine IGFBP-2
and human IGFBP-3 (9–11), and all of these studies indicated
that there were major contributions to the IGF-binding site
provided by both the N- and C-terminal domains. Further-
more, others have demonstrated that isolated N- and C-
terminal domains of IGFBP-3 cooperate in the presence of
IGFs to form high affinity complexes (3). Our previous un-
published biosensor work has shown that the mouse and
human IGFBP-5 proteins have identical affinities for binding
IGFs.
A considerable body of work from several groups indi-
cates that the major IGF-binding site is contained within the
N-terminal domain (see Fig. 1), and an important nuclear
magnetic resonance study localized this site to a hydrophobic
patch on the surface of the IGFBP-5 protein (6). Subsequently,
it was shown that substituting specific hydrophobic residues
in this region of IGFBP-5 resulted in a large reduction in IGF-I
binding (12), and more recently, our group was able to con-
firm by circular dichroism (CD) spectroscopy that these mu-
tations do not cause a gross alteration in protein structure,
and are, therefore, likely to be specific for IGF binding (13).
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Until recently, less attention had focused on identifying
the C-terminal residues in IGFBPs that are involved in IGF
interaction. There is a region common to the C-terminus of
IGFBP-5 and -3 that is rich in basic amino acids (between
201–218 in IGFBP-5, where 10 of the 18 residues are basic Arg
or Lys). Several of these basic amino acids have been shown
to play a critical role in IGFBP-5 binding to a wide variety of
different molecules, including heparin (14, 15), extracellular
matrix (ECM) (16), the ECMproteins osteopontin and throm-
bospondin (17), acid-labile subunit (18), a putative IGFBP-5
receptor (19), and plasminogen activator inhibitor-I (20), in
addition to acting as a nuclear localization signal (reviewed
in Ref. 21). However, it has also been demonstrated that
mutagenesis of up to four of the basic amino acids simulta-
neously had very little effect on IGF-I binding, as measured
by solution phase binding assays, and it was concluded that
these basic residues were not involved in the IGF/IGFBP
interaction (22).
We have previously demonstrated that two nonbasic
amino acids (G203 and Q209) in IGFBP-5, which lie within
the basic 201–218 region and are completely conserved in all
six binding proteins from those species studied, are involved
in IGF binding (13, 23, 24). We also showed that the equiv-
alent amino acids in IGFBP-2 were involved in IGF binding
(13); more recently, others have demonstrated that this is also
true for IGFBP-3 (25).We have argued that this demonstrates
physical overlap of IGF- and heparin-binding sites in the
C-terminal domain of both IGFBP-5 and -3.
In the present study we extended our mutagenesis strat-
egy of the 201–218 region of IGFBP-5, by ultimately substi-
tuting all 10 basic Lys and Arg amino acids to Ala residues
(creating the C-Term A through C-Term E series of mutants;
see Fig. 1). We generated mutants that involved the basic
residuesK202 andK208, situated immediately adjacent to the
residues involved in IGF binding, as well as a mutant in
which a third basic residue, K206, which lies spatially as well
as sequentially between the two IGF-binding residues, was
mutated. We compared the IGF-I-binding abilities of these
mutants with that of the wild-type (wt) protein by ligand
blotting, solution phase IGF binding assays, and biosensor
real-time analysis of binding kinetics. Furthermore, we car-
ried out CD analysis on both wt IGFBP-5 and C-Term E
mutant protein to establish whether the effects of these mu-
tations are specific for IGF binding and not the result of a
major conformational change in protein structure.
IGFBP-5 has been shown to have both inhibitory and en-
hancing effects on IGF actions (21). We hoped in this study
to examine whether mutations that influence the ability of
IGFBP-5 to interact with both IGF-I and the extracellular
environment would help to provide mechanistic explana-
tions for these apparently conflicting biological properties of
IGFBP-5. To this end, we measured the survival of human
breast cancer MCF-7 cells plated on the ECM components
fibronectin, collagen, and laminin. Inhibitory effects of
IGFBP-5mutants on cell survivalwere determined by adding
IGF-I and either wt IGFBP-5 or its various mutants after cell
attachment, whereas enhancement of IGF-I action was ob-
served when IGF-I and various IGFBP proteins were pre-
bound to the substratum before cell attachment.
Materials and Methods
Site-directed mutagenesis
The full-length cDNAs for rat IGFBP-5 in pGEM-7zf (Promega Corp.,
Madison, WI), containing both initiator and signal peptide, was pro-
vided by Dr. S. Guenette (John Wayne Cancer Institute, Los Angeles,
CA). Site-directed mutagenesis was carried out using the QuikChange
FIG. 1. Schematic representation of the
amino acid substitutionsmade for theN-Term
mutant and the C-Term series of mutants re-
ported in this paper. The IGFBP-5 protein
structure is divided up into the N-terminal,
central, and C-terminal domains. The hydro-
phobic patch constituting themajor IGF-bind-
ing site is shown in gray in the N-terminal
domain, as is the 201–218 region in the C-
terminal domain. Single-letter code and posi-
tions of the amino acids thatweremutated are
indicated, and the residues that these were
substituted for are shown adjacent in gray.
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system (Stratagene, La Jolla, CA) following the protocol provided by the
manufacturer. The rat and mouse protein sequences of IGFBP-5 differ
by only a single amino acid at position 188 (Asp and Glu, respectively).
Site-directed mutagenesis was employed to convert wt rat to wt mouse
sequences (D188E) as described previously (13). This was then used as
a template to make C-Term A (R214A) using the oligonucleotides 5-
GCAGTGCAAGCC TTC TGCAGGCCGCAAACG TGGCAT-3 and
5-GATGCCACGTTTGCGGCCTGCAGAAGGCTTGCACTGC-3.
C-Term A was then used as a template to make C-Term B (K202A:
K208A:R214A) using the oligonucleotides 5-CTG TGA CCG CGCAGG
ATTCTACAAGAGAGCTCAGTGCAAGC-3 and 5-GCT TGCACT
GAG CTC TCT TGT AGA ATC CTG CGC GGT CAC AG-3. C-Term B
was then used as a template to make C-Term C (R201A:K202A:K206A:
K208A:R214A) using the oligonucleotides 5-CCC AAC TGT GAC GCC
GCAGGATTCTACGCGAGAGCTCAGTG-3 and 5-CACTGAGCT
CTC GCG TAG AAT CCT GCG GCG TCA CAG TTG GG-3. C-Term C
was then used as a template to make C-Term D (R201A:K202A:K206A:
R207A:K208A:K211A:R214A) using the oligonucleotides 5-GAT TCT
ACG CGG CAG CTC AGT GCG CGC CTT CTG CAG G-3 and 5-CCT
GCA GAA GGC GCG CAC TGA GCT GCC GCG TAG AAT C-3.
C-Term D was then used as a template to make C-Term E (R201A:
K202A:K206A:R207A:K208A:K211A:R214A:R216A:K217A:R218A) us-
ing the oligonucleotides 5-CGC GCC TTC TGC AGG CGC CGC AGC
TGGCATCTGCTGGTGTGTGG-3 and 5-CCACACACCAGCAGA
TGCCAGCTGCGGCGCCTGCAGAAGGCGCG-3. N-Term (K68N:
P69Q:L70Q:L73Q:L74Q) was made as described previously (13). All
oligos were synthesized by MWG BioTech (Ebersberg, Germany). After
site-directed mutagenesis, automated DNA sequencing (Lark Technol-
ogies, Takeley, UK) was carried out on all clones to confirm that the
correct mutations had been made.
Bacterial expression and purification of recombinant
proteins
The expression of recombinant IGFBP-5 proteins was carried out
using conditions identical with those described previously (13). After
cell lysis, the fusion proteins were extracted from the soluble fraction
only and subsequently subjected to two rounds of purification. Cell
lysates were loaded onto glutathione-Sepharose columns (Amersham
Biosciences, Little Chalfont, UK), and the purified IGFBPs were then
eluted after removal of the glutathione-S-transferase tag with PreScis-
sion protease (Amersham Biosciences). Subsequently, the untagged IG-
FBPs were purified by reverse phase HPLC (RP-HPLC) using a poly-
meric column (PLRP-S; 300 Å; 8 m; diameter, 4.6  150 mm; Polymer
Laboratories Ltd., Church Stretton, UK) equilibrated at 30 C with a
mobile phase consisting of 3 parts solution A (0.1% trifluoroacetic acid
in water) and 1 part solution B (0.1% trifluoroacetic acid in acetonitrile).
Aliquots (1–2 ml) of affinity-purified protein [2–3 mg/ml in 50 mm Tris
HCl (pH 7), 150 mm NaCl, and 1 mm EDTA] were injected onto the
column, which was run at 1 ml/min throughout. After 5 min of isocratic
elution, a linear gradient from 25% solution B to 40% solution B was
applied over the next 50 min. Absorbance of column effluent was mon-
itored at 220 nm; IGFBP proteins were collected, typically between 25
and 30 min after sample injection, and assessed for homogeneity by
SDS-PAGE (Fig. 2). Gels were stained with 0.3% (wt/vol) Coomassie
Brilliant Blue R-250 (Sigma-Aldrich Corp., Poole, UK), 5% (vol/vol)
methanol, and 7.5% (vol/vol) glacial acetic acid for 30 min and then
destained in 30% (vol/vol) methanol and 10% (vol/vol) glacial acetic
acid for 1 h with shaking, followed by fresh destaining, without shaking
overnight. The gel was dried using the EasyBreeze system (Hoefer
Scientific Instruments, San Francisco, CA) according to the manufac-
turer’s instructions.
A single chromatography under these conditions usually yielded
200–600 g pure protein, which was lyophilized to remove HPLC elu-
ants then stored at 70 C. Proteins were redissolved, as required, in
buffer appropriate for their subsequent experimental use.
CD spectroscopy and fluorescence
To compare the secondary structures of wt IGFBP-5 and C-Term E
proteins, CD spectropolarimetry data were recorded using a Jasco J-810
spectropolarimeter (Easton, MD) in cells with a path length of 0.02 cm
(far UV) using protein concentrations of 0.25 mg/ml for both wild-type
and mutant IGFBP-5 samples (time constant, 0.2 sec; scan speed, 50
nm/min; eight scans). The secondary structure contents of wild-type
and C-Term Ewere estimated using the CONTIN procedure (26), which
was accessible from the DICHROWEBwebsite (27). Secondary structure
estimates were obtained using data values down to 185 nm in both the
wt and C-Term E proteins. Fluorescence spectra were recorded using a
PerkinElmer LS50B fluorometer (Wellesley, MA) in 1-cm path length
cells using a protein concentration of 0.1 mg/ml for both wt and mutant
samples (excitation, 290 nm; slits of 5 nm band pass).
Biosensor analysis
Reagents for biosensor analysis were purchased from BiaCore Ltd.
(Stevenage, UK). Biosensor studies were performed with a Biacore 3000
instrument using protocols previously described, where IGF-I was the
immobilized ligand present on the biosensor chip surface and thewt and
mutant IGFBP-5 proteins were present in the mobile phase as analyte
(13). Each proteinwas analyzed at five different doubling concentrations
(0–50 nm), and IGFBP-5 proteins were injected randomly in duplicate
across IGF-I surfaces. Analysis of data assumed a fully reversible 1:1
stoichiometry of binding between IGFBP and immobilized IGF, and the
Langmuir model provided in the BiaEvaluation 3.1 software and the
global data analysis option were used to fit data as described previously
(13). Under the conditions described we observed no mass transport-
associated effects. The methods used to investigate the interaction be-
tween wt and mutant IGFBP-5 proteins and heparin-coated biosensor
surfaces have been described in detail previously (28). The wt and
mutant proteins were analyzed for heparin binding at concentrations
between 0–400 nm.
Solution phase IGF binding assay
Solution phase binding assays were performed as described previ-
ously (13), except that in this case, RP-HPLC-purified proteins were
analyzed.
Assessment of biological activity of IGFBP-5 mutants
The human breast cancer line MCF-7 was routinely maintained in
DMEM supplementedwith 10% fetal calf serum, 0.29mg/ml glutamine,
100U/ml penicillin, and 100g/ml streptomycin at 37 C in 5%CO2. Cell
culture reagents were purchased from Invitrogen (Paisley, Scotland,
UK).
Inhibition of the IGF-I response by IGFBP-5 mutants
Ninety-six-well tissue culture plates were coated with 1 g/ml fi-
bronectin, collagen, or laminin in PBS (pH 7.4). Fibronectin (F-0635),
FIG. 2. Coomassie-stained gel of the wt and various mutant proteins
after glutathione-S-transferase and HPLC purification. A single pro-
tein species was observed in each case. We also noted the size dif-
ferences between the various proteins analyzed: the mature (minus
signal peptide) wt mouse IGFBP-5 protein (28,461 Da) and the N-
terminal pentapeptide extension (GPLGS) from pGEX-6P1 is 28,872
Da. The alanine substitutions in the 201–218 region of the C-Term
mutant series result in a progressive reduction in size down to the
C-TermEmutant at 28,112Da,whereas themutations inN-term lead
to an increase in size to 28,934 Da.
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laminin (L-2020), and collagen (C-7661) were obtained from Sigma-
Aldrich Corp. Wells were rinsed twice, and approximately 1  104
MCF-7 cells/well were plated in DMEM/1% BSA and cultured over-
night to allow attachment.Wellswere rinsed again, and IGF-I (10 ng/ml)
and various concentrations of wt or mutant IGFBP-5 (as indicated in the
figures)were added inDMEM/1%BSA, for an additional 72 h of culture.
Wells containing IGFBP-5 without IGF-I were included as controls. The
cells were then fixed with 4% (wt/vol) paraformaldehyde and stained
with 1 mg/ml crystal violet. The stain was solubilized in 0.1% Triton
X-100, and the OD was read at 540 nm.
Enhancement of the IGF-I response by IGFBP-5 mutants
Ninety-six-well tissue culture plates were coated with 1 g/ml fi-
bronectin, collagen, or laminin in PBS, pH 7.4. Wells were rinsed and
blocked with DMEM/1% BSA for 1 h at 37 C. IGF-I (1000 ng/ml) and
wt or mutant IGFBP-5 (1000 ng/ml) were added either individually or
in combination inDMEM/0.1%BSA and incubated overnight at 4 C. The
wells were then rinsed to remove unbound IGF-I and IGFBP-5, and
approximately 1  104 MCF-7 cells/well were plated in DMEM/0.1%
BSA and cultured for 72 h. The cells were fixed with 4% (wt/vol)
paraformaldehyde and stained with 1 mg/ml crystal violet. The stain
was solubilized in 0.1% Triton X-100, and the OD was read at 540 nm.
Binding and dissociation studies of IGF-I/IGFBP-5
complexes
Determination of IGF-I release. Ninety-six-well tissue culture plates were
coated with 1 g/ml fibronectin, collagen, or laminin in PBS (pH 7.4).
Wells were rinsed and blocked with DMEM/1% BSA for 1 h at 37 C.
IGFBP-5 (1000 ng/ml) and 100,000 cpm [125I]IGF-I were added in PBS/
0.1% BSA and incubated overnight at 4 C. In experiments measuring
initial binding, 1000 ng/ml unlabeled IGF-I was added to the tracer to
achieve equivalent concentrations to those used in the enhancement
studies described above. Total binding was determined by rinsing the
wells with DMEM/1% BSA before eluting the bound material with 200
l 200 mm HCl, incubated at room temperature for 30 min. To measure
dissociation of [125I]IGF-I, wells were rinsed, and 200 l PBS/0.1% BSA
(pH 7.4) was added. Incubation was continued at 37 C, and the medium
containing dissociated IGF-Iwas sampled at intervals. Radioactivitywas
measured in a -counter (LKB Instruments, Gaithersburg, MD).
Determination of IGFBP-5 release. To determine binding and release of
IGFBP-5, 96-well culture plates were coated with laminin, collagen, or
fibronectin as described above, and each IGFBP-5 preparation (1000
ng/ml) was added to the well along with IGF-I (1000 ng/ml) and
incubated overnight at 37 C. Unbound IGFBP-5 was removed by aspi-
ration, the wells were rinsed, and the aspirates were combined for
determination of unbound IGFBP-5. Fresh medium was added, and the
wells were then incubated for an additional 24 h at 37 C, after which the
medium was removed to determine dissociated IGFBP-5. The quantity
of IGFBP-5 in all samples was determined by RIA as previously de-
scribed (29), using each IGFBP-5 mutant as its own standard (although
the antiserum recognized all the mutants with very similar avidity).
Results
After RP-HPLC purification, we obtained a single protein
species for all the clones in this study, as indicated by SDS-
PAGE followed by Coomassie Brilliant Blue staining (Fig. 2).
Figure 3A and Table 1 show that the secondary structure
estimates for wt IGFBP-5 and C-Term E determined by near
and farUVCDspectroscopywere similar, exhibiting a strong
negative band with a minimum of 202 nm in each case. The
overall shapes of these spectra were very similar and indi-
cated high proportions of random coil type structure in each
case. Secondary structure estimates of these spectra gave low
percentages of -helical structure and suggested that the
proteins contain a greater proportion of -sheet, -turns, and
other structures (Table 1). To examine the conformational
flexibility of IGFBP-5, bothwt and C-Term Emutant proteins
were analyzed in the presence of 50% trifluoroethanol (TFE).
TFE has a lower dielectric constant than water, thus pro-
moting intramolecular interactions by minimizing the inter-
actions of the protein with the surrounding solvent mole-
cules. In the presence of TFE, both proteins adopted very
similar conformations that were more helical (Fig. 3A). The
structural flexibility of IGFBP-5 may be important for its
mode of interaction with the ECM or cell surfaces, thus
providing a point of control in its ability to bind IGF. The
fluorescence emission spectra showed that wt IGFBP-5 and
C-Term E have very similar emission maxima around 385
nm, indicating that the tryptophan residues are fully exposed
to solvent in each protein (Fig. 3B).
FIG. 3. A, Far UV CD spectra with and with-
out TFE of wt IGFBP-5 (solid line) and C-
Term E mutant (dashed line) proteins using
values obtained by Bradford assay (wt, 0.5
mg/ml; C-Term, E 0.47 mg/ml). B, Fluores-
cence emission spectra of wt IGFBP-5 (solid
line) and the C-Term E mutant (dashed line).
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Detailed assessment of IGF/IGFBP binding affinities were
obtained by biosensor analyses. Sensorgrams derived from
biosensor analysis of wt and mutant IGFBP-5 binding to
immobilized IGF-I sensor chips are presented in Fig. 4. The
equilibrium constant obtained for the wt IGFBP-5 protein
was almost identical with that reported previously (13) (0.2
nm). An examination of the derived equilibrium constants in
Table 2 indicated an almost progressive decrease in affinity
as mutations of basic amino acids within the C-terminal
201–218 region of IGFBP-5 accumulate, although we noted
that C-Term D had a slightly higher affinity for IGF-I than
C-Term B and C. This resulted in a mutant C-term D, which
had a similar KD to that of C-Term A and C-Term B, but had
increases in both Ka and Kd rate constants. Additional mu-
tations produced a mutant, C-Term E, which had a KD value
of 3.5 nm, almost 15-fold lower than thewt protein.However,
the affinity of the N-terminal mutant (13) was the most com-
promised, with a KD value of 10.9 nm, 45-fold lower than that
of wt IGFBP-5. This progressive loss in binding to immobi-
lized IGF was also observed in IGF-II ligand blotting (data
not shown).
We examined the affinity of these mutant proteins in a
solution phase analysis of the IGF-I-IGFBP interaction (Fig.
5). It was clear from the saturation binding curves obtained
that there was a progressive reduction in affinity for IGF-I
from wt IGFBP-5 through the C-Term A–E series mutants to
the N-term mutant, although we noted again that C-Term D
had a slightly higher affinity for IGF-I than C-Term C (Fig.
5). A linear transformation, bymeans of a semilog plot, of the
solution phase assay data allowed calculation of the quantity
of each mutant required to bind an equivalent amount of
[125I]IGF-I (data not shown). The fold differences in IGF-I
binding relative to the wt protein were very minor ( 2-fold)
from C-Term A–D, whereas C-Term E and N-Term again
showedmajor impairments in their binding to IGF-I (33- and
44-fold reductions in binding, respectively).
Biosensor analysis was also used to study the interaction
of the wt IGFBP-5 protein and the various mutants with
heparin immobilized to the sensor chip (Fig. 6). The affinity
of interaction for the wt protein was 7.22 2.22 nm (mean
se; n  4), which is similar to that reported previously (28).
For the C-Term A mutant, the value was 21.3  0.6 (aver-
age  range; n  2), which indicates a slight reduction in
heparin binding,whereas binding of theC-TermB-Emutants
to heparin was so low that affinity constants could not be
derived. For N-Term, there was a 2-fold reduction in the
affinity (mean  se, 15.1  4.0 nm; n  4) relative to the wt
protein, although this was not statistically significant (P 
0.05). The loss in binding to immobilized heparin was also
observed by ligand blotting (data not shown).
IGF-I exhibited a dose-dependent increase in MCF-7 cell
survival independent of the substratum, achieving a maxi-
mal response at approximately 10 ng/ml (results not shown).
However, the phenotype of the cells was substratum depen-
dent, because cells grown on collagen or fibronectin exhib-
ited an adherent phenotype, whereas those grown on lami-
nin exhibited a much greater cell-cell interaction, with
minimal cell-substratum interaction (Fig. 7).
IGFBP-5 was able to inhibit the effects of IGF-I in a dose-
dependent manner regardless of substratum, whereas C-
TABLE 1. Secondary structural estimations of wt and C-Term E
mutant proteins
Contin -Helix -Sheet -Turn Other NMRSD
wt 6.4 20.3 15.2 58.0 0.070
 50% TFE 37.9 6.4 22.5 33.2 0.256
C-Term E 6.0 21.6 15.0 57.5 0.082
 50% TFE 38.2 5.8 23.8 32.1 0.229
NMRSD, Nuclear magnetic resonance study.
FIG. 4. Biosensor analysis of IGF-I binding. Individual sensograms
for wt IGFBP-5, C-Term A–E, and N-Term binding to human IGF-I
ligand, which was covalently captured by amine coupling chemistry
to the carboxymethyl surface of a CM5 biosensor chip. SeeMaterials
and Methods for the details of the collection and analysis of data and
the concentrations of IGFBP-5 proteins present as analyte in these
experiments.
TABLE 2. Biosensor-derived kinetic and equilibrium constants
for interaction of wtIGFBP-5, C-Term-A to -E, and N-Term
proteins binding to immobilized IGF-I
Ka (M1 s1  105) Kd (104 s1) KD (nM) -Fold
wt IGFBP-5 21.3 5.1 0.24 1
C-Term A 6.3 4.3 0.68 2.8
C-Term B 4.9 5.6 1.1 4.6
C-Term C 5.1 6.1 1.2 5.0
C-Term D 7.6 6.9 0.91 3.8
C-Term E 2.3 8.3 3.5 14.6
N-Term 2.0 21.9 10.9 45.4
KD is derived as Kd/Ka. The fold reduction in binding of mutant
proteins relative to wt protein is indicated in the right column. For
additional details see Materials and Methods.
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Term E and N-Term mutants were virtually ineffective (Fig.
8A). More conservative mutants (C-Term A and B) were also
effective inhibitors of IGF-I, although therewas a progressive
diminution of this inhibitory activity such that C-TermDwas
largely ineffective (Fig. 8B). In the absence of IGF-I, IGFBP-5
had no effect on cell number (results not shown).
Figure 9A shows the ability of wt IGFBP-5 to enhance the
effects of IGF-I on various substrata. Although IGF-I in-
creased cell numbers by approximately 50% when added
without IGFBP-5, in the presence of IGFBP-5, cell numbers
were increased by approximately 100%. These effects of IGF-I
and IGFBP-5 were independent of the substratum upon
which the cells had attached. Furthermore, IGFBP-5, when
added in the absence of IGF-I, failed to influence cell num-
bers. Figure 9B shows the enhancement effect for all mutants.
Once again, C-Term A and B possessed activities similar to
that of wt IGFBP-5. However, in contrast to their limited
inhibitory potential, C-Term C–E were as effective as wt
IGFBP-5 in augmenting the actions of IGF-I when captured
on the substratum (Fig. 9B). However, N-Term was com-
pletely ineffective in this assay, adding additional support to
the conclusion that the effects of IGFBP-5 in this systemwere
dependent upon interaction with IGF-I. The discrepancy be-
tween the inhibitory and enhancing effects of the mutants
was explained by determining the capture and release of
IGF-I from the substratum. IGFBP-5 bound to the substratum
was capable of binding approximately 30% of the IGF-I
added,whereas in the absence of IGFBP-5, less than 1%of the
IGF-I bound directly to the substratum. There was a pro-
gressive decrease in the amount of IGF-I bound to IGFBP-5
on the substratum with increasing number of mutations,
although C-Term D bound more than anticipated (Fig. 10A).
Despite the fact that all the C-Termmutants bound less IGF-I
than wt IGFBP-5 during the culture period, some of the
mutants released more IGF-I than did wt IGFBP-5 (Fig. 10B),
and when expressed as a proportion of the amount bound,
all the mutants released considerably more than wt IGFBP-5.
Thus, althoughwt IGFBP-5 released approximately 5% of the
total IGF-I bound during the first 24 h of culture, C-Term E
released almost 20% (Fig. 10C). Once again, however, C-
TermDbehaved anomalously, releasing proportionately less
IGF-I. These findings were again independent of the sub-
stratum. Because the release of bound IGF-I was dependent
both upon its release from IGFBP-5 and upon the release of
IGFBP-5 from the substratum, we examined IGFBP-5 release
under identical conditions using an IGFBP-5 RIA. Seventy-
five to 85% of wt IGFBP-5 added to the cultures was bound,
independent of the substratum used (Fig. 11A). Similar
amounts of the mutants were also bound, with the exception
of C-TermE, inwhich thiswas approximately 50–70%.How-
ever, during the first 24 h in culture, progressively more
FIG. 6. Biosensor analysis of heparin binding. Individual sensograms
for wt IGFBP-5, C-TermA–E, andN-Term binding to heparin coupled
to the surface of a CM5 biosensor chip. Experimental procedures were
exactly as described previously (28).
FIG. 5. Solution phase assay of IGF-I binding to wt and
mutant IGFBP-5 proteins. The wt IGFBP-5 (F), C-Term A
(E), C-Term B (f), C-Term C (), C-Term D (Œ), C-Term E
(‚), and N-Term () were purified by HPLC (see above).
Binding was assayed by incubation of proteins overnight
with 25,000–30,000 cpm [125I]human IGF-I and measure-
ment of bound ligand by the method described previously
(13). This experiment was repeated twice with similar re-
sults.
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IGFBP-5 was released with increasing number of mutations
(again with the exception of C-Term D; Fig. 11B) Thus, ap-
proximately 2% of wt IGFBP-5, N-Term and C-Term D, were
released from the substratum, whereas this dissociation in-
creased progressively for the other mutants, reaching ap-
proximately 10% for C-Term E (Fig. 11C). Note also that the
proportion of IGF-I released (Fig. 10C) was consistently ap-
proximately twice the proportion of IGFBP-5 released (Fig.
11C).
Overall, these results suggest a faster dissociation of the
IGFBP-5 mutants from the substratum as part of the expla-
nation for the increased bioavailability of IGF-I despite their
reduced ability to sequester IGF-I onto the substratum dur-
ing the association phase.
Discussion
At the outset of this study it was considered essential to
establish whether the effects on IGF-I binding of our amino
acid substitutions in the IGFBP-5 sequence were specific or
were simply the effect of a gross conformational change in
protein structure. CD spectra were obtained to compare the
secondary structures of wt IGFBP-5 and C-Term E, and these
were virtually superimposable. Furthermore, the fluores-
cence spectra for both wt IGFBP-5 and C-Term E gave emis-
sion maxima of around 385 nm, indicating that the single
tryptophan residue in both proteinswas similarly orientated.
Therefore, both fluorescence and CD structural analyses in-
dicated that the overall secondary and tertiary structures of
IGFBP-5 were not disrupted by the mutation, to alanine, of
the 10 basic amino acids between 201 and 218.
Although we have previously reported that G203 and
Q209 are important residues in the C-terminal domain of
IGFBP-5 involved in IGF-I binding, we were unable to con-
clude that these were the only C-terminal residues involved
in this function (13). However, substitution of the two basic
residues adjacent to G203 and Q209 had only a small (2-
fold) effect on the KD. This adds additional support to the
belief that residues G203 and Q209 are indeed critical for
interaction with IGF-I, rather than reflecting a global change
in the IGFBP-5 molecule as a result of mutagenesis. Further-
more, an additional mutation, K206A, which is predicted to
lie on the same face of the molecule, juxtaposed between the
two IGF-binding residues, had no effect on the KD for IGF-I.
However, we have demonstrated that mutation of all the
basic Arg or Lys residues in the 201–218 region of IGFBP-5
ultimately produces a significant 15-fold reduction in affinity
for ligand, as determined by biosensor analysis, although this
was still less than that induced by mutation of the N termi-
nus, which resulted in a 45-fold decrease in affinity for IGF-I.
At first sight, there would appear to be a discrepancy
between our data and those of Parker et al. (22), who reported
only very minor reductions in IGF-I binding when they sub-
stituted certain basic residues in this region of IGFBP-5.
However, our solution phase data actually agree very well
with their data when only a limited number of basic residues
are mutated. The only mutant that is identical in the two
studies is C-TermA (R214A), which their Scatchard analysis,
derived from solution phase assays, demonstrated to have a
1.22-fold reduction in IGF-I binding relative to the wt
IGFBP-5 protein, which compares well with the 1.35-fold
reduction for this mutant in our study. Furthermore, the
greatest number of simultaneous substitutions of basic res-
iduesmade byParker et al. (22) is four (R201A:K202N:K206N:
K208N), and this mutant had a 1.15-fold reduction in IGF-I
affinity. This is a very similar combination of mutations to
our C-Term C mutant, which only has one extra residue
mutated, (R201A:K202A:K206A:K208A:R214A) and has a
1.63-fold reduction in IGF-I binding in our solution phase
FIG. 7. MCF-7 cells grown in the absence (A and C) or
presence (B and D) of IGF-I on laminin (A and B) or
fibronectin (C and D). Cells on laminin demonstrate
reduced cell-substratum interactions. Although cells on
fibronectin demonstrate a flattened morphology indic-
ative of cell-substratum contact, IGF-I induced a shift
toward greater cell-cell contact, although these cells re-
tained numerous cellular projections in contact with the
substratum.
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assays. Even C-Term D, with seven basic residues substi-
tuted, still demonstrated less than a 2-fold reduction in bind-
ing. The differences in affinity estimates thus seem to reside
in the nature of the system used to determine it, rather than
differences between laboratories. At present it is not possible
to say which basic amino acids in the 201–218 region of
IGFBP-5 contributemost quantitatively to IGF-I binding, and
it may be that certain combinations of mutations are more
effective than others in reducing affinity for ligand.Although
our more sensitive biosensor analysis recorded slightly
larger reductions in IGF-I binding for C-Term A–D, the most
significant reduction in IGF-I binding (15-fold) only occurred
whenwemutated all 10 basic residues in C-TermE. Thus, the
major effect on IGF binding in this study occurred with
mutation of residues 216, 217, and 218 at the extreme C-
terminal end of this region. Two of these residues (217 and
216) are in close proximity with residues 203 and 209, re-
spectively, within a helical wheel alignment of the amino
acids in this region, originally presented by Parker et al. (22).
Definitive proof that the IGF-binding site primarily includes
residues 203, 209, 216, and 217 will only be obtained once the
crystal structure of the C-terminal domain of IGFBP-5 is
determined, and its contact with IGF-I is resolved in detail.
Recently, others have examined the IGF-II-binding site in
the C-terminal domain of IGFBP-6 by nuclear magnetic res-
onance (30). IGFBP-6 is unique among the IGFBP family in
that it has a much higher affinity for IGF-II than IGF-I. Nev-
ertheless, among the IGFBPs, IGFBP-5 has the highest bind-
ing affinity for both IGF-II and IGF-I. Although, IGFBP-6
shares seven of the 10 basic amino acids in the equivalent
C-terminal region as 201–218 in IGFBP-5, the nuclear mag-
netic resonance study indicated that the main IGF-II-binding
site involved three nonbasic residues (not including the
equivalent G203 and Q209 residues in IGFBP-5). However,
these researchers also showed that although mutating these
three residues to alanines decreased binding to IGF-II, it had
no effect on binding to IGF-I (30). Therefore, it may be that
this particular site is only involved in binding IGF-II and
confers on IGFBP-6 its unique preference for binding this
growth factor. Certainly, in our present studymutation of the
basic residues in the 201–218 region of IGFBP-5 led to pro-
gressive loss of binding to biotinylated IGF-II in ligand blot
analysis (data not shown).
Although this present study clearly indicates a role for
some or all of the basic residues in the 201–218 region of
IGFBP-5 in binding IGF-I, it is crucial to remember that this
region also contains a major heparin-binding site in both
IGFBP-5 and -3, which has previously been shown to be
FIG. 8. Inhibition of IGF-I-mediated MCF-7 cell survival by wt IGFBP-5 (wt), C-Term E and N-Term (A), or wt and mutants C-Term A-D (B)
cultured on laminin, collagen, or fibronectin. Values are the means of triplicate wells.
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involved in binding to heparin and components of the ECM
(14, 16). Although we demonstrated a minor contribution in
heparin binding from R214, because C-Term A had only a
slight reduction in binding to the heparin-coated biosensor
chip, we found that C-Term B displayed a very sharp de-
crease in binding to levels below which affinity constants
could be calculated. This is what we expected, because this
mutant has one of the basic residues, K208, substituted in the
putative classical heparin-binding motif (XBBBXXBX, where
X is any amino acid, and B is basic) between YKRKQCKP
(205–212). Taken together, these findings support the argu-
ment that within the C terminus of IGFBP-5, and probably
also within IGFBP-3, there is overlap of residues involved in
IGF-I and heparin binding, with IGF binding including 203,
209, 216, and 217, and heparin binding spanning 205–212.
This has important implications for the biological actions of
these two IGFBPs, because it implies that any of the numer-
ous functions ascribed to the 210–218 region in IGFBP-5 may
also impact upon IGF-I binding. Other functions ascribed to
this region include binding to the acid-labile subunit, the
putative IGFBP-5 receptor, and plasminogen activator in-
hibitor-I in addition to acting as a nuclear localization signal
(21). In support of this hypothesis, others have clearly dem-
onstrated that incubation of IGFBP-5 with heparin resulted
in a 17-fold decrease in the affinity for IGF-I (31). These
researchers argued that this lowering of the affinity of
IGFBP-5 for IGF-I when 201–218 is bound by heparin may be
critical in obtaining the correct balance between free and
bound growth factors. Furthermore, recent biosensor anal-
yses from our laboratory have shown that prebinding
IGFBP-5with IGF-I inhibits the subsequent association of the
binding protein with heparin, and conversely, that heparin
prebound to IGFBP-5 inhibits the association of the binding
protein with biosensor surfaces containing immobilized
IGF-I (28). This led us to conclude that binding of IGF-I and
heparin to IGFBP-5 is partly competitive in nature.
Although MCF-7 cells produce several IGFBPs, including
IGFBP-5, the concentrations of IGFBP-5 used in this study
were designed tomimic those occurring during involution of
the mammary gland in vivo, which are typically 3 orders of
magnitude greater than those in MCF-7 cultures. When we
examined the biological activities of the C-Termmutants, we
discovered that their ability to inhibit IGF-mediated cell sur-
vival was correlated with their affinity for IGF-I. However,
C-TermDwas an exception, because it had aKD intermediate
between that ofC-TermAandB, but its ability to inhibit IGF-I
was considerably reduced. This particular mutant had dif-
ferent kinetics in terms of its interaction with IGF-I, because
it had increases in both Ka and Kd, suggesting a more ki-
netically dynamic binding complex. This, in turn, suggests
that slower kinetic interactions favor inhibitory effects, pre-
sumably by reducing the likelihood of dissociation, which
would decrease the prospect of binding to the IGF receptor.
In contrast, the ability to enhance the actions of IGF-I was
largely unaffected in any of the mutants, even C-Term E,
which was incapable of inhibiting IGF-I in the liquid phase.
The retention of this biological activity of the mutants ap-
peared to be explained by a faster dissociation of IGF-I from
the substratum (where it was bound via IGFBP-5) due to
increases in Kd and is similar in concept to the interaction of
FIG. 9. Enhancement of the actions of IGF-I by IGFBP-5 when precomplexed and bound to the solid phase. A, Ability of wt IGFBP-5 to enhance
the effect of IGF-I independent of the substratum. B, Enhancement of IGF-I action by wt IGFBP-5 and mutants. The enhancement is defined
as the increase in cell number over and above that by IGF-I alone (calculated for wt IGFBP-5 by subtracting column 4 from column 2 in A).
Values are the mean  SEM of four experiments, except for N-Term (n  2).
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IGFBP-5 with heparin, which reduces its affinity for IGF-I
and results in enhancement of IGF actions. However, given
that mutations in the C-terminal domain of IGFBP-5 led to
reductions in both the affinity for IGF-I and that for the
substrata, it was important to define which of these had the
greatest influence on the release, and hence the bioavailabil-
ity, of IGF-I. Examination of the dissociation of IGFBP-5
mutants from the substratum revealed that dissociation was
progressively enhanced with increasing number of muta-
tions (again with the exception of C-Term D), implying that
increased release of IGF-I:IGFBP-5 complexes was able to at
least partially explain the enhancing capabilities of the
IGFBP-5 mutants despite their reduced ability to bind IGF-I.
However, the proportion of IGF-I released from the substra-
tum consistently exceeded (by 	2-fold) the proportion of
IGFBP-5 released, suggesting that dissociation of IGF-I from
the IGFBP-5 that remained bound to the substratum also
made a contribution to the bioavailability of IGF-I. Thus, we
conclude that the increased proportional bioavailability of
IGF-Iwhen bound to IGFBP-5mutants in thismodel involves
two processes, and these contribute approximately equal
quantities of IGF-I: firstly, a more rapid release of IGFBP-5
mutants from the substratum (and presumably subsequent
dissociation of IGF-I from that IGFBP-5), and secondly, dis-
sociation of IGF-I from IGFBP-5, which remained bound to
the substratum. These actions of IGFBP-5 mutants appeared
to be largely independent of whether cells exhibited a phe-
notypewith extensive cell-substratum interactions (fibronec-
tin and collagen) or a predominantly cell-cell contact (lami-
nin). Because C-Term E was completely ineffective in terms
of inhibition of IGF actions, but retained its ability to enhance
IGF-I, this mutant represents an IGFBP-5 molecule with ex-
clusively enhancing actions.
In summary, we have demonstrated that basic residues
adjacent to residues in the region 201–218 important for IGF
binding have little effect on affinity for IGF, supporting our
previous conclusions that residues G203 and Q209 are im-
portant for the interaction with IGF-I. However, cumulative
mutagenesis of the basic amino acids in the 201–218 region
of IGFBP-5 led to a progressive loss of IGF-I binding. Ulti-
mately, this produced a 15-fold reduction in binding when
all 10 basic residues were mutated to alanines, an effect that
was not due to gross conformational changes in protein
structure. The ability of IGFBP-5 mutants to inhibit the ac-
tions of IGF-I on cell survival inMCF-7 cells showed a strong
correlation with their relative affinities for IGF-I, determined
by biosensor analysis, suggesting that affinity for IGF-I is an
important factor in this biological property of IGFBP-5. How-
ever, we also identified that a mutant C-Term D, with a KD
similar to those of othermutants, butwith faster kinetics, had
a much reduced inhibitory capacity, indicating that the ki-
netics of the interaction with IGF-I are also important in
FIG. 10. Binding and dissociation of
[125I]IGF-I/IGFBP-5 complexes to laminin,
collagen, or fibronectin. A, Quantity of IGF-I
bound after 24 h of culture. After washes to
remove unbound IGF-I, the quantity of radio-
labeled IGF-I released from the substratum
during the subsequent 24 h of culture was
determined and is shown in B. The proportion
of IGF-I released is shown in C. Note that the
binding and release of IGF-I from N-Term
IGFBP-5 were not significantly different from
the binding and release of IGF-I in the absence
of any IGFBP-5 (results not shown). Values
are the mean  SEM of three experiments.
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determining this property. In stark contrast to this, the af-
finity of IGFBP-5 mutants for IGF-I had no predictive value
with respect to their ability to enhance the effects of IGF-I
when bound to components of the ECM. Our results dem-
onstrate that it is possible to engineer IGFBP-5mutants (such
as C-Term E) that have exclusively IGF-enhancing effects.
Whether it is possible to generate IGFBP-5 mutants with
exclusively inhibitory effects remains to be determined. This
study does not take account of possible IGF-independent
effects of such mutants, which are the subject of current
studies.
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